Accretion Pharmaceuticals IPO

Accretion Pharmaceuticals Ltd

₹1,15,200 /1200 sharesMinimum Investment

Accretion Pharmaceuticals IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
--₹101.00₹79.00-₹22.00 (21.78%)

Accretion Pharmaceuticals IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
14 May ‘25 - 16 May ‘25₹1,15,2001,200₹96 - ₹101
Issue SizeIPO Doc
29.75Cr
RHP PDF

Subscription rate

As of 16 May'25, 05:00 PM
Qualified Institutional Buyers4.78x
Non-Institutional Investor3.48x
Retail Individual Investor8.86x
Total6.13x

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited is a pharmaceutical company involved in the manufacturing and marketing of various healthcare products. The company's product portfolio includes tablets, capsules, oral liquids, external preparations such as ointments, creams, gels, lotions, medicated shampoos, mouthwash, and dusting powders, as well as oral powders like sachets and dry syrups. Additionally, Accretion Pharmaceuticals offers contract manufacturing services, producing pharmaceutical products for various marketers on a loan licence or contract basis. The company's manufacturing facility is located at Xcelon Ind Park in Vasna Chacharvadi, Ahmedabad, Gujarat, and has been operational since 2014. Accretion Pharmaceuticals is ISO certified under standards ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018. The company was converted from a partnership firm to a limited company in 2023.;
Founded in
2012
Managing director
Mr Vivek Ashok Kumar Patel
Parent organisation
Accretion Pharmaceuticals Ltd

Strengths & Financials of Accretion Pharmaceuticals

Strengths
Risks
The company claims to offer a wide range of healthcare products, including tablets, capsules, ointments, and oral powders. Accretion Pharmaceuticals believes its diverse product offerings have helped establish a strong customer base both in domestic and international markets.
The company is ISO 9001:2015 certified for quality management systems, ISO 14001:2015 certified for environmental management, and ISO 22000:2018 certified for food safety management systems.
The company has seen a consistent increase in revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 22.29 crore in FY22 to Rs 29.38 crore in FY23 and Rs 33.66 crore in FY24. PAT also increased from Rs 0.08 crore in FY22 to Rs 0.10 crore in FY23 and Rs 3.87 crore in FY24.

Accretion Pharmaceuticals Financials

*All values are in Rs. Cr
No Graph Data To Display

Application Details of Accretion Pharmaceuticals IPO

Apply asPrice bandApply upto
Regular96 - 101₹2 Lakh
High Networth Individual96 - 101₹2 - 5 Lakh
For Accretion Pharmaceuticals IPO, eligible investors can apply as Regular.
ⓒ 2016-2025 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 6.0.7
STOCK MARKET INDICES:  S&P BSE SENSEX |  BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW